Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 87-93

  Fogari, Roberto ^a   Mugellini, Amedeo ^a   Preti, Paola ^a   Zoppi, Annalisa ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Angiotensin receptor blocker; Combination therapy; Losartan; Valsartan

Indexed keywords

AMLODIPINE; LOSARTAN; PLACEBO; VALSARTAN;

ADULT; AGED; ANKLE EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 77950826146     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s9404     Document Type: Article

References (32)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560-2572.
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension/ European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
3. Turnbull E. Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
4. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 1, 2003. J Hypertens. 2003;21:1055-1076.
5. Hansson L, Zanchetti A, Carruthers SG, et al; for the HOT study group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med. 2000;342:145-153.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-2997.
9. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am J Hypertens. 1998;11: 73S-78S.
10. Sica DA. Rationale for fixed dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-462.
11. Mancia G, De Backer G, Dominiczak A, et al; for the Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
12. Erratum in: J Hypertens. 2007; 25:1749.
13. Kjeldsen SE, Aksnes TA, de la Sierra A, et al. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy. 2007;4:31-40.
14. Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy. 2005;25:1213-1229.
15. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008;10(1 Suppl 1):27-32.
16. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220-224.
17. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.
18. Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press. 1992;1:113-119.
19. Parati G, Bosi S, Castellano M. Guidelines for 24 hour non invasive ambulatory blood pressure monitoring: report from a working group of the Italian Society of Hypertension. High Blood Press. 1995;4:168-174.
20. Omboni S, Parati G, Zanchetti A, Mancia G. Circulation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens. 1995;13:1105-1112.
21. Rizzoni D, Castellano M, Muiesan ML, Porteri E, Agabiti Rosei E. Beyond trough:peak ratio. A new index of the smoothness of the antihypertensive effect of a drug. High Blood Press. 1997;6:110-115.
22. Parati G, Omboni S, Tizzoni D, Agabiti Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685-1691.
23. Gokhale N, Shahani S, Pawar D. Efficacy and safety of losartanamlodipine combination an Indian postmarketing surveillance experience. J Indian Med Assoc. 2002;100(3):207-208.
24. Kohlmann O Jr, Oigman W, Mion D Jr, et al. The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol. 2006;86:39-51.
25. Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008;10:185-194.
26. Greg L, Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs. 2008;68:373-281.
27. Chung O, Csikós T, Unger T. Angiotensin II receptor pharmacology and AT1-receptor blockers. J Hum Hypertens. 1999;13 (Suppl 1):S11-20.
28. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999;33:850-855.
29. Stamler R. Implications of the INTERALSALT. Study. J Hypertens. 1991;17 (Suppl 1):116-120.
30. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality. A meta analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
31. Julius S, Kjeldsen SE, Weber M, et al. for the VALUE trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or anlodipine:the value randomised trial. Lancet. 2004;363:2022-2031.
32. Palatini P, Penzo M, Racioppa A, et al. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med. 1992;152:1855-1860.